PHILADELPHIA—A novel treatment for chronic kidney disease (CKD) patients with anemia is showing positive results following a Phase 1/2 clinical trial, according to findings reported at Kidney Week 2011.
The Epodure Biopump, a tissue-based platform technology that continuously produces and delivers proteins using a patient’s own skin biopsy, was found to be well-tolerated and showed no adverse effects in 6-30 months of treatment. In 20 and 40 IU/kg per day dosages in 13 patients, researchers found no formation of anti-erythropoietin (EPO) antibodies as well as no serum EPO levels that went above 60 mU/mL.
In addition, Epodure elevated hemoglobin levels and maintained those levels above 9 g/dL in more than 12 patients for more than three months.
Epodure is manufactured by Medgenics, Inc. based in Israel and San Francisco.